Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

Fig. 2

Multivariate analysis of baseline predictors to the first SIE. a RCT CZP group. b All CZP group. A Cox proportional hazards model fitted with AACI categories was used to identify baseline covariates linked to SIE risk (p ≤ 0.25). Baseline covariates identified as risk factors (p ≤ 0.05) are highlighted in red. No other baseline covariates examined (BMI, disease duration, HAQ-DI, and MTX dose) were considered relevant to the outcome (p > 0.25). SIE Serious infectious event, RCT Randomized controlled trial, CZP Certolizumab pegol, AACI Age-adjusted comorbidity index, DAS28(CRP) 28-joint Disease Activity Score with C-reactive protein, BMI Body mass index, HAQ-DI Health Assessment Questionnaire Disability Index, MTX Methotrexate, RCT CZP Patients randomized to CZP in the RAPID1/RAPID2 randomized controlled trials, All CZP All patients treated with CZP during the RAPID1/RAPID2 randomized controlled trials and/or open label extensions

Back to article page